Oyster Therapeutics Lands $60M to Take Protein Degraders Into the Brain
Oyster Therapeutics raised $60M led by 4BIO, with Eli Lilly participating, to advance a brain-penetrant oral tau degrader built on disassembly chemistry for Alzheimer's and other neurodegenerative diseases.
TAG V-5496 · 751 words on the filing

Summary of findings
- Oyster Therapeutics raised $60M in a Series A-2 led by 4BIO Capital; Eli Lilly joined as a new investor.
- Lead preclinical candidate is an oral degrader of pathological tau for Alzheimer's disease; no clinical timeline disclosed.
- SELFTAC molecules disassemble to cross the intestinal wall and blood-brain barrier, then reassemble inside neurons.
- Prior £25M (~$33M) Series A in 2022 was co-led by Syncona and Oxford Science Enterprises.
- Competing tau-lowering RNA programs: Biogen's diranersen Phase 2 and Arrowhead's ARO-MAPT Phase 1/2, with data expected in 2027.
Oyster Therapeutics has raised $60 million to push brain-penetrant small molecule protein degraders toward the clinic, with a lead preclinical candidate engineered to degrade pathological tau in Alzheimer's disease. The London-based startup, formerly known as Kesmalea Therapeutics, announced the Series A-2 financing last week.
4BIO Capital led the round. New investors included Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures; earlier backers Syncona, Oxford Science Enterprises, Mission BioCapital, and MGB Ventures also participated. Lilly's involvement carries weight — the company markets Kisunla, an amyloid-targeting antibody for Alzheimer's.
What does the financing change for the degradation field?
Protein degradation has proven itself in oncology — the first degraders reached the market this year — and the approach is spreading into immunology. Neurology has remained closed. The problem is physical: a heterobifunctional degrader carries one moiety that binds the target protein and another that recruits the degradation-marking enzyme, and the resulting molecule runs large relative to conventional small molecules.
Oyster CEO Rob Johnson laid out the sequence of obstacles. "But for protein degraders destined for the brain, the first obstacle is actually the gut," he said — the molecule's size blocks intestinal absorption, and whatever survives must still cross the blood-brain barrier. Johnson noted that many degrader programs across the industry have been shelved over this size problem.
Oyster's answer is a molecule that disassembles into two smaller fragments capable of permeating biological membranes — the intestinal wall and the blood-brain barrier — then reassembles inside the target cell, such as a neuron, to direct the disease protein to the proteasome. The platform is named SELFTAC.
"It is chemistry that has been used in previously approved pharmaceuticals," Johnson said. "The human body has been exposed to these particular chemical groups. We're just using them in a unique way."
Why target tau with a degrader?
Tau lacks an active site where a classic small molecule inhibitor could bind, which has pushed developers toward RNA medicines. Biogen's antisense oligonucleotide diranersen (formerly BIIB0880) binds tau-encoding mRNA; in May the company reported preliminary Phase 2 data showing tau reduction and cognitive benefit in Alzheimer's patients, though the trial missed its primary goal of demonstrating dose response on a rating scale at week 76. Biogen will present new Phase 2 data this week at the CTAD conference in Boston.
Arrowhead Pharmaceuticals is running Phase 1/2 testing of ARO-MAPT, an siRNA that silences the tau-coding gene. Last month the company reported interim data showing tau reduction in healthy volunteers; the trial continues, with additional data expected in 2027.
Johnson acknowledged these programs but framed the modality gap. RNA candidates lower all tau, including the healthy form that neurons need and that occurs at high concentration in the brain. Pathological tau forms insoluble aggregates in Alzheimer's brains, and an intermediary form — the protein transitioning from healthy to pathological — takes on a shape that Oyster's drug can selectively target, leaving healthy tau untouched.
An oral degrader adds practical advantages: lower manufacturing cost than RNA medicines, room-temperature stability, and dosing without injection or infusion. That profile matters as the field moves toward treating patients who show biological signs of disease but no symptoms.
"What modality is going to win in that pre-symptomatic patient population?" Johnson asked. "An injectable is going to be a tough sell. If you have a safe oral solution, that's got to be the end goal, and that's what we're aiming for."
Where does Oyster go next?
Johnson said the new cash will bring the tau degrader to the clinic, though he declined to give a timeline. SELFTAC could extend to other neurological proteins; Johnson pointed to misfolded alpha-synuclein in Parkinson's disease as the most obvious next target. Oyster has not disclosed a Parkinson's program, but Johnson confirmed interest in the disease and said the degradation approach could also apply to cancer.
The company rests on the research of founder and Chief Scientific Officer Harry Finch, a medicinal chemist who spent the Covid-19 pandemic working on the degrader size problem. Oyster raised £25 million (about $33 million) in a 2022 Series A co-led by Syncona and Oxford Science Enterprises.
The rebrand from Kesmalea carries its own logic, per Johnson: "An oyster can take a grain of sand and turn it into a beautiful pearl. Oysters also have a cleansing role and degrading is sort of cleansing the brain from pathologic forms of protein."
via businesswire.com (Original)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- K-8919
- V-8592
- E-6700
- V-7932
- P-6323